A vast majority of cancer deaths occur as a result of metastasis. Unfortunately, effective
treatments for metastases are currently lacking due to the difficulty of selectively targeting …

Novel treatment approaches are needed to overcome innate and acquired mechanisms of
resistance to current anticancer therapies in cancer cells and the tumour immune …

Background Postoperative progression and chemotherapy resistance is the major cause of
treatment failure in patients with triple-negative breast cancer (TNBC). Currently, there is a …

Tumor progression and the efficacy of immunotherapy are strongly influenced by the
composition and abundance of immune cells in the tumor microenvironment. Due to the …

Background Although immune checkpoint inhibitor (ICI) is regarded as a breakthrough in
cancer therapy, only a limited fraction of patients benefit from it. Cancer stemness can be the …

Accumulating evidence suggests that pyroptosis, apoptosis and necroptosis are deeply
involved in cancer immunity. However, the role of PANoptosis in gastric cancer (GC) …

Clinically relevant immunological biomarkers that discriminate between diverse
hypofunctional states of tumor-associated CD8+ T cells remain disputed. Using multiomics …

Despite remarkable clinical efficacy of immune checkpoint blockade (ICB) in cancer
treatment, ICB benefits for triple-negative breast cancer (TNBC) remain limited. Through …

Ferroptosis is a type of cell death related to cancer; however, the characteristics of
ferroptosis in cancers are still uncertain. Based on the data in The Cancer Genome Atlas, we …

Association with hypomethylating agents is a promising strategy to improve the efficacy of
immune checkpoint inhibitors-based therapy. The NIBIT-M4 was a phase Ib, dose-escalation …